Codexis, Inc. (CDXS)

Codexis (CDXS) stock has experienced a significant decline over the past year. Key events include Q3 2025 financials showing decreased revenue, a Supply Assurance Agreement with Merck combined with workforce reduction, analyst revisions, insider selling, and increased short interest.

Demand seasonality for Codexis, Inc. is influenced by customer manufacturing schedules and clinical trial progression, leading to revenue variability. The company's strategic pivot towards innovative manufacturing solutions for complex therapeutics, particularly in oligonucleotide manufacturing, is a key driver, and its success depends on market adoption.

Codexis, Inc. is a protein engineering company based in Redwood City, California, specializing in innovative enzyme solutions for the healthcare sector. They utilize their CodeEvolver® platform to develop enzymes with improved activity, selectivity, and stability. Their products and services include custom biocatalysts for various applications and the ECO Synthesis™ manufacturing platform for RNAi therapeutics.

Codexis, Inc. provides enzymatic solutions and services globally, with a presence in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company's headquarters are located in Redwood City, California, U.S.

Codexis is recognized for its protein engineering capabilities and CodeEvolver® technology platform. They have partnerships with leading organizations and are known for their role in scaling RNA therapeutics through the ECO Synthesis® Manufacturing Platform. The company emphasizes its commitment to sustainable biocatalysis.

Codexis, Inc. has 252 institutional owners and shareholders holding a total of 82,782,830 shares. Major institutional owners include Opaleye Management Inc., Standard Life Aberdeen plc, BlackRock, Inc., and Vanguard Group Inc. Individual insiders hold approximately 2.04% of the company's shares.